TP53 and breast cancer: In summary, our research identified a novel whole-genome sequencing method to quantify the CIN and we found high CIN status was correlated with poor DFS as well as the copy loss of TP53 in BRCA1 germline mutation breast cancer, while the distribution of the mutation sites along the BRCA1 gene did not affect the CIN value.